ArticleAntimicrobial agents and chemotherapy2013
Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Synergy between immune system and antibiotics drives infection control in mice.Frontiers in immunology · 2025Article
- Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.Physiological reviews · 2024Review
- Innate immune responses in pneumonia.Pneumonia (Nathan Qld.) · 2023Review
- Harnessing the Potential of Enzymes as Inhaled Therapeutics in Respiratory Tract Diseases: A Review of the Literature.Biomedicines · 2022Review
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Therapeutic evaluation of immunomodulators in reducing surgical wound infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.Antibiotics (Basel, Switzerland) · 2021Review
- Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and EnhancesAntimicrobial agents and chemotherapy · 2021Article
- Nonclassical antagonism between human lysozyme and AMPs against Pseudomonas aeruginosa.FEBS open bio · 2021Article
- Lysozyme-Induced Transcriptional Regulation of TNF-α Pathway Genes in Cells of the Monocyte Lineage.International journal of molecular sciences · 2019Article
- Nanomedical Relevance of the Intermolecular Interaction Dynamics-Examples from Lysozymes and Insulins.ACS omega · 2019Article
- Selective permeability of mucus barriers.Current opinion in biotechnology · 2018Review
- Stabilization of a Virus-Like Particle and Its Application as a Nanoreactor at Physiological Conditions.Biomacromolecules · 2017Article
- Review
- Article
- Endogenous antimicrobial factors in the treatment of infectious diseases.Central-European journal of immunology · 2016Review
- Genetically enhanced lysozyme evades a pathogen derived inhibitory protein.ACS chemical biology · 2015Article
- Fusion with a cell wall binding domain renders autolysin LytM a potent anti-Staphylococcus aureus agent.FEMS microbiology letters · 2015Article
- The Natural Antimicrobial Enzyme Lysozyme is Up-Regulated in Gastrointestinal Inflammatory Conditions.Pathogens (Basel, Switzerland) · 2014Review
- Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections.BioengineeredArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of drug-resistant bacterial pathogens is a growing global concern and has prompted an effort to explore potential adjuvant and alternative therapies derived from nature's repertoire of bactericidal proteins and peptides. In humans, the airway surface liquid layer is a rich source of antibiotics, and lysozyme represents one of the most abundant and effective antimicrobial components of airway secretions. Human lysozyme is active against both Gram-positive and Gram-negative bacteria, acting through several mechanisms, including catalytic degradation of cell wall peptidoglycan and subsequent bacterial lysis. In the infected lung, however, lysozyme's dense cationic character can result in sequestration and inhibition by polyanions associated with airway inflammation. As a result, the efficacy of the native enzyme may be compromised in the infected and inflamed lung. To address this limitation, we previously constructed a charge-engineered variant of human lysozyme that was less prone to electrostatic-mediated inhibition in vitro. Here, we employ a murine model to show that this engineered enzyme is superior to wild-type human lysozyme as a treatment for mucoid Pseudomonas aeruginosa lung infections. The engineered enzyme effectively decreases the bacterial burden and reduces markers of inflammation and lung injury. Importantly, we found no evidence of acute toxicity or allergic hypersensitivity upon repeated administration of the engineered biotherapeutic. Thus, the charge-engineered lysozyme represents an interesting therapeutic candidate for P. aeruginosa lung infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.